Skip to main content

Advertisement

Table 9 Projected health impact of the GPELF (2000–2014) over lifetime of the benefit cohorts

From: The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)

Benefit cohort Number of chronic cases averted (millions) Years of chronic disease averted (millions) Number of acute (ADL) episodes averted (millions) DALYs averted (millions)a
1. Protected from acquiring infection 21 938 2,157 103 (68–147)
2. Subclinical morbidity prevented from progressing 12 551 1,267 62 (41–88)
3. Alleviated clinical disease 3 104 1,264 11 (8–16)
Total 36 1,592 4,689 175 (116–250)
  1. aRange based on the 95 % uncertainty interval of the disability weight (Table 7)
  2. See Additional file 2: Table S3 for the results stratified by WHO region. ADL acute adenolymphangitis